Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Oncogene
    August 2021
  1. LI H, Qi Z, Niu Y, Yang Y, et al
    FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer.
    Oncogene. 2021 Aug 6. pii: 10.1038/s41388-021-01957.
    >> Share

    June 2021
  2. ZHANG J, Guan W, Xu X, Wang F, et al
    A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01891.
    >> Share

  3. WU Y, Guo Q, Ju X, Hu Z, et al
    HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.
    Oncogene. 2021 Jun 19. pii: 10.1038/s41388-021-01884.
    >> Share

  4. WU YH, Huang YF, Chang TH, Chen CC, et al
    COL11A1 activates cancer-associated fibroblasts by modulating TGF-beta3 through the NF-kappaB/IGFBP2 axis in ovarian cancer cells.
    Oncogene. 2021 Jun 11. pii: 10.1038/s41388-021-01865.
    >> Share

    May 2021
  5. TAN J, Zheng X, Li M, Ye F, et al
    C/EBPbeta promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    Oncogene. 2021 May 8. pii: 10.1038/s41388-021-01788.
    >> Share

    April 2021
  6. LINDZEN M, Ghosh S, Noronha A, Drago D, et al
    Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.
    Oncogene. 2021 Apr 30. pii: 10.1038/s41388-021-01784.
    >> Share

    January 2021
  7. YOSHIDA K, Yokoi A, Sugiyama M, Oda S, et al
    Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01595.
    >> Share

  8. NOH K, Bach DH, Choi HJ, Kim MS, et al
    The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.
    Oncogene. 2021;40:384-395.
    >> Share

    October 2020
  9. ZHANG Q, Zhou W, Yu S, Ju Y, et al
    Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation.
    Oncogene. 2020 Oct 20. pii: 10.1038/s41388-020-01516.
    >> Share

  10. RANZUGLIA V, Lorenzon I, Pellarin I, Sonego M, et al
    Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
    Oncogene. 2020;39:6370-6386.
    >> Share

    September 2020
  11. XU Z, Li X, Li H, Nie C, et al
    Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01482.
    >> Share

  12. MEHNER C, Miller E, Hockla A, Coban M, et al
    Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
    Oncogene. 2020 Sep 14. pii: 10.1038/s41388-020-01451.
    >> Share

    July 2020
  13. NAIR J, Huang TT, Murai J, Haynes B, et al
    Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
    Oncogene. 2020 Jul 9. pii: 10.1038/s41388-020-1383.
    >> Share

    May 2020
  14. LI J, Alvero AB, Nuti S, Tedja R, et al
    CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.
    Oncogene. 2020;39:3965-3979.
    >> Share

    April 2020
  15. PELLARIN I, Dall'Acqua A, Gambelli A, Pellizzari I, et al
    Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
    Oncogene. 2020 Apr 24. pii: 10.1038/s41388-020-1292.
    >> Share

  16. KAN T, Wang W, Ip PP, Zhou S, et al
    Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites.
    Oncogene. 2020 Apr 13. pii: 10.1038/s41388-020-1288.
    >> Share

    March 2020
  17. CHOI PW, So WW, Yang J, Liu S, et al
    MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread.
    Oncogene. 2020 Mar 25. pii: 10.1038/s41388-020-1264.
    >> Share

  18. TAMURA R, Yoshihara K, Nakaoka H, Yachida N, et al
    XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
    Oncogene. 2020 Mar 2. pii: 10.1038/s41388-020-1237.
    >> Share

  19. HAYASHI T, Sano K, Aburatani H, Yaegashi N, et al
    Initialization of epithelial cells by tumor cells in a metastatic microenvironment.
    Oncogene. 2020;39:2638-2640.
    >> Share

    February 2020
  20. CHEN C, Gupta P, Parashar D, Nair GG, et al
    ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
    Oncogene. 2020 Feb 6. pii: 10.1038/s41388-020-1194.
    >> Share

    January 2020
  21. KWEON J, Jang AH, Shin HR, See JE, et al
    A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants.
    Oncogene. 2020;39:30-35.
    >> Share

    November 2019
  22. CLUZET V, Devillers MM, Petit F, Chauvin S, et al
    Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.
    Oncogene. 2019 Nov 19. pii: 10.1038/s41388-019-1109.
    >> Share

  23. KIM YS, Gupta Vallur P, Jones VM, Worley BL, et al
    Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells.
    Oncogene. 2019 Nov 13. pii: 10.1038/s41388-019-1097.
    >> Share

  24. SUN C, Li X, Guo E, Li N, et al
    MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.
    Oncogene. 2019 Nov 8. pii: 10.1038/s41388-019-1090.
    >> Share

  25. ASARE-WEREHENE M, Nakka K, Reunov A, Chiu CT, et al
    The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.
    Oncogene. 2019 Nov 7. pii: 10.1038/s41388-019-1087.
    >> Share

    September 2019
  26. TUNG CH, Kuo LW, Huang MF, Wu YY, et al
    MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
    Oncogene. 2019 Sep 30. pii: 10.1038/s41388-019-1025.
    >> Share

  27. ZHAO L, Wang W, Xu L, Yi T, et al
    Correction: Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2019 Sep 3. pii: 10.1038/s41388-019-0896.
    >> Share

  28. ZHANG MH, Zhang HH, Du XH, Gao J, et al
    UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kappaB pathway.
    Oncogene. 2019 Sep 2. pii: 10.1038/s41388-019-0987.
    >> Share

    August 2019
  29. HAN Y, Kim B, Cho U, Park IS, et al
    Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
    Oncogene. 2019 Aug 13. pii: 10.1038/s41388-019-0949.
    >> Share

    July 2019
  30. KLEINSCHMIDT EG, Miller NLG, Ozmadenci D, Tancioni I, et al
    Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.
    Oncogene. 2019 Jul 15. pii: 10.1038/s41388-019-0881.
    >> Share

  31. HARDY LR, Pergande MR, Esparza K, Heath KN, et al
    Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
    Oncogene. 2019 Jul 11. pii: 10.1038/s41388-019-0842.
    >> Share

  32. CHEN X, Mangala LS, Mooberry L, Bayraktar E, et al
    Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
    Oncogene. 2019 Jul 9. pii: 10.1038/s41388-019-0862.
    >> Share

  33. MAJEM B, Parrilla A, Jimenez C, Suarez-Cabrera L, et al
    MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.
    Oncogene. 2019 Jul 5. pii: 10.1038/s41388-019-0860.
    >> Share

    March 2019
  34. JEONG KJ, Park SY, Cho KH, Sohn JS, et al
    Correction: The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Oncogene. 2019 Mar 29. pii: 10.1038/s41388-019-0769.
    >> Share

    February 2019
  35. JOHN B, Naczki C, Patel C, Ghoneum A, et al
    Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.
    Oncogene. 2019 Feb 14. pii: 10.1038/s41388-019-0728.
    >> Share

  36. INESS AN, Felthousen J, Ananthapadmanabhan V, Sesay F, et al
    The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.
    Oncogene. 2019;38:1080-1092.
    >> Share

    January 2019
  37. HUANG CC, Cheng SH, Wu CH, Li WY, et al
    Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
    Oncogene. 2019 Jan 9. pii: 10.1038/s41388-018-0658.
    >> Share

  38. JING Y, Zhang Y, Zhu H, Zhang K, et al
    Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.
    Oncogene. 2019 Jan 7. pii: 10.1038/s41388-018-0644.
    >> Share

    December 2018
  39. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0637.
    >> Share

  40. GRABOSCH S, Bulatovic M, Zeng F, Ma T, et al
    Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
    Oncogene. 2018 Dec 5. pii: 10.1038/s41388-018-0581.
    >> Share

    November 2018
  41. ZHAO L, Wang W, Xu L, Yi T, et al
    Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0577.
    >> Share

    October 2018
  42. MCLEAN K, Tan L, Bolland DE, Coffman LG, et al
    Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0523.
    >> Share

    September 2018
  43. ZHONG Y, Yang S, Wang W, Wei P, et al
    The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.
    Oncogene. 2018 Sep 28. pii: 10.1038/s41388-018-0512.
    >> Share

    August 2018
  44. SUN J, Cai X, Yung MM, Zhou W, et al
    miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2018 Aug 30. pii: 10.1038/s41388-018-0459.
    >> Share

    July 2018
  45. HODGKINSON K, Forrest LA, Vuong N, Garson K, et al
    GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.
    Oncogene. 2018 Jul 4. pii: 10.1038/s41388-018-0377.
    >> Share

  46. ZHOU W, Sun W, Yung MMH, Dai S, et al
    Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
    Oncogene. 2018;37:3981-3997.
    >> Share

    June 2018
  47. OZES AR, Pulliam N, Ertosun MG, Yilmaz O, et al
    Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Oncogene. 2018;37:3589-3600.
    >> Share

    May 2018
  48. AL HABYAN S, Kalos C, Szymborski J, McCaffrey L, et al
    Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0317.
    >> Share

  49. GABBASOV R, Xiao F, Howe CG, Bickel LE, et al
    NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0296.
    >> Share

  50. RADA M, Nallanthighal S, Cha J, Ryan K, et al
    Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Oncogene. 2018 May 17. pii: 10.1038/s41388-018-0297.
    >> Share

  51. BERNS K, Caumanns JJ, Hijmans EM, Gennissen AMC, et al
    ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Oncogene. 2018 May 15. pii: 10.1038/s41388-018-0300.
    >> Share

    April 2018
  52. DORAYAPPAN KDP, Wanner R, Wallbillich JJ, Saini U, et al
    Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.
    Oncogene. 2018 Apr 11. pii: 10.1038/s41388-018-0189.
    >> Share

    February 2018
  53. MITAMURA T, Pradeep S, McGuire M, Wu SY, et al
    Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).
    Oncogene. 2018;37:722-731.
    >> Share

  54. LIU Y, Zhou H, Zhu R, Ding F, et al
    SPSB3 targets SNAIL for degradation in GSK-3beta phosphorylation-dependent manner and regulates metastasis.
    Oncogene. 2018;37:768-776.
    >> Share

  55. LADANYI A, Mukherjee A, Kenny HA, Johnson A, et al
    Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
    Oncogene. 2018 Feb 5. pii: 10.1038/s41388-017-0093.
    >> Share

    January 2018
  56. AKHTER MZ, Sharawat SK, Kumar V, Kochat V, et al
    Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0106.
    >> Share

  57. GHANNAM-SHAHBARI D, Jacob E, Kakun RR, Wasserman T, et al
    PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0040.
    >> Share

  58. RUSSO A, Czarnecki AA, Dean M, Modi DA, et al
    PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0097.
    >> Share

  59. GRITHER WR, Divine LM, Meller EH, Wilke DJ, et al
    TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0043.
    >> Share

  60. NAGARAJ AB, Wang QQ, Joseph P, Zheng C, et al
    Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
    Oncogene. 2018;37:403-414.
    >> Share

  61. CORKERY DP, Clarke LE, Gebremeskel S, Salsman J, et al
    Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Oncogene. 2018;37:174-184.
    >> Share

    October 2017
  62. WANG J, Kho DH, Zhou JY, Davis RJ, et al
    MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
    Oncogene. 2017;36:5939-5947.
    >> Share

    September 2017
  63. BIAN X, Gao J, Luo F, Rui C, et al
    PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Oncogene. 2017 Sep 25. doi: 10.1038/onc.2017.
    >> Share

  64. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    >> Share

  65. YAMAGUCHI H, Du Y, Nakai K, Ding M, et al
    EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    >> Share

  66. GUO H, Zhu Q, Yu X, Merugu SB, et al
    Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
    Oncogene. 2017;36:5098-5109.
    >> Share

    August 2017
  67. SOMASAGARA RR, Spencer SM, Tripathi K, Clark DW, et al
    RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
    Oncogene. 2017 Aug 14. doi: 10.1038/onc.2017.
    >> Share

    June 2017
  68. TO SKY, Mak ASC, Eva Fung YM, Che CM, et al
    beta-catenin downregulates Dicer to promote ovarian cancer metastasis.
    Oncogene. 2017 Jun 26. doi: 10.1038/onc.2017.
    >> Share

  69. KLYMENKO Y, Kim O, Loughran E, Yang J, et al
    Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    >> Share

    May 2017
  70. ZHAO J, Wang Y, Mu C, Xu Y, et al
    MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
    Oncogene. 2017 May 1. doi: 10.1038/onc.2017.
    >> Share

    April 2017
  71. NIU N, Mercado-Uribe I, Liu J
    Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    >> Share

    March 2017
  72. SHANG Y, He J, Wang Y, Feng Q, et al
    CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    >> Share

  73. BASULI D, Tesfay L, Deng Z, Paul B, et al
    Iron addiction: a novel therapeutic target in ovarian cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    >> Share

  74. COMISSO E, Scarola M, Rosso M, Piazza S, et al
    OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    >> Share

  75. GUPTA R, Yang Q, Dogra SK, Wajapeyee N, et al
    Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    >> Share

    February 2017
  76. HWANG MH, Cho KH, Jeong KJ, Park YY, et al
    RCP induces Slug expression and cancer cell invasion by stabilizing beta1 integrin.
    Oncogene. 2017;36:1102-1111.
    >> Share

  77. HARJES U, Bridges E, Gharpure KM, Roxanis I, et al
    Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.
    Oncogene. 2017;36:912-921.
    >> Share

  78. LAU TS, Chan LK, Wong EC, Hui CW, et al
    A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFalpha-TGFalpha-EGFR.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    >> Share

    January 2017
  79. ZHAO L, Ji G, Le X, Luo Z, et al
    An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.
    Oncogene. 2017 Jan 23. doi: 10.1038/onc.2016.
    >> Share

    December 2016
  80. MODI DA, Tagare RD, Karthikeyan S, Russo A, et al
    PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.
    >> Share

  81. GURLER MAIN H, Xie J, Muralidhar GG, Elfituri O, et al
    Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.
    Oncogene. 2016 Dec 12. doi: 10.1038/onc.2016.
    >> Share

    November 2016
  82. WILSON C, Qiu L, Hong Y, Karnik T, et al
    The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    >> Share

  83. DIMITROVA N, Nagaraj AB, Razi A, Singh S, et al
    InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    >> Share

    October 2016
  84. MATSUURA K, Huang NJ, Cocce K, Zhang L, et al
    Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    >> Share

  85. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    >> Share

  86. WITT AE, Lee CW, Lee TI, Azzam DJ, et al
    Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    >> Share

    September 2016
  87. FANG D, Chen H, Zhu JY, Wang W, et al
    Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2016 Sep 12. doi: 10.1038/onc.2016.
    >> Share

    June 2016
  88. DE CIAN MC, Pauper E, Bandiera R, Vidal VP, et al
    Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016